Clal Insurance Enterprises Holdings Ltd Sells 9,994 Shares of Eli Lilly and Company $LLY

Clal Insurance Enterprises Holdings Ltd cut its position in Eli Lilly and Company (NYSE:LLY) by 10.2% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 88,051 shares of the company’s stock after selling 9,994 shares during the period. Clal Insurance Enterprises Holdings Ltd’s holdings in Eli Lilly and Company were worth $80,987,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in LLY. Meiji Yasuda America Inc grew its stake in Eli Lilly and Company by 2.8% in the first quarter. Meiji Yasuda America Inc now owns 11,072 shares of the company’s stock valued at $10,184,000 after acquiring an additional 304 shares during the period. Temasek Holdings Private Ltd raised its position in shares of Eli Lilly and Company by 47.0% during the first quarter. Temasek Holdings Private Ltd now owns 173,259 shares of the company’s stock worth $159,358,000 after purchasing an additional 55,412 shares during the period. Danica Pension Livsforsikringsaktieselskab bought a new position in shares of Eli Lilly and Company during the 1st quarter valued at about $53,773,000. ABN Amro Investment Solutions grew its position in shares of Eli Lilly and Company by 23.2% in the 1st quarter. ABN Amro Investment Solutions now owns 169,151 shares of the company’s stock valued at $155,580,000 after purchasing an additional 31,877 shares during the period. Finally, Oslo Pensjonsforsikring AS bought a new stake in Eli Lilly and Company during the 1st quarter worth approximately $2,733,000. 82.53% of the stock is owned by institutional investors.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Several market commentary pieces highlighted Lilly’s leadership in GLP-1 obesity treatments, its expanding pipeline, and the view that its growth outlook remains strong despite intensifying competition from Novo Nordisk.
• Positive Sentiment: Analyst-focused coverage continued to point to Lilly’s momentum from Zepbound and Mounjaro, with investors still treating the company as a core winner in the fast-growing weight-loss and diabetes market.
• Positive Sentiment: Broader healthcare stocks also moved higher, which likely provided a supportive backdrop for Eli Lilly shares during the session.
• Neutral Sentiment: Eli Lilly defended its advertising, saying its comparisons are based on the SURMOUNT-5 trial, while noting Novo’s criticism centers on the use of older dose comparisons rather than direct head-to-head data.
• Negative Sentiment: Novo Nordisk sued Eli Lilly in U.S. federal court, accusing the company of false and misleading advertising for Zepbound and Mounjaro and seeking to stop the ads, force corrective marketing, and recover damages. Reuters article about the lawsuit

Analyst Ratings Changes

A number of equities research analysts recently commented on LLY shares. Barclays raised their price objective on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a report on Monday, May 4th. UBS Group increased their target price on Eli Lilly and Company from $1,250.00 to $1,425.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Jefferies Financial Group upped their price target on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the stock a “buy” rating in a research report on Tuesday, June 9th. BMO Capital Markets reiterated an “outperform” rating on shares of Eli Lilly and Company in a report on Monday, June 15th. Finally, Berenberg Bank boosted their price target on shares of Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the stock a “hold” rating in a research report on Monday, June 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $1,283.64.

Eli Lilly and Company Trading Up 2.5%

LLY stock opened at $1,175.15 on Wednesday. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The company has a fifty day moving average price of $1,126.19 and a two-hundred day moving average price of $1,037.68. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,249.45. The stock has a market cap of $1.11 trillion, a price-to-earnings ratio of 41.75, a price-to-earnings-growth ratio of 1.44 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The company had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. Eli Lilly and Company’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same quarter last year, the company posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities analysts anticipate that Eli Lilly and Company will post 34.55 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be given a $1.73 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is presently 24.58%.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.